AstraZeneca today announced that it has completed its agreement with Tillotts Pharma AG (Tillotts), part of the Zeria Group, for the divestment of global rights, outside the US, to Entocort ® (budesonide), a gastroenterology medicine for patients with mild to moderate Crohn’s disease and ulcerative colitis. Upon completion of the transaction, Tillotts paid AstraZeneca $215 million for the rights to sell and develop Entocort capsules and enema formulations outside the US. The transaction does not include the transfer of any AstraZeneca employees or facilities. The agreement reinforces AstraZeneca’s strategic focus on three main therapy areas. As AstraZeneca will no longer retain an interest in the ex-US rights to Entocort, the upfront receipt will be reported in Other Operating Income in the Company’s financial statements for 2015. The transaction does not impact AstraZeneca’s financial guidance for 2015. About Entocort® In capsule formulation, Entocort is a first-line therapy indicated for the induction and maintenance of clinical remission of mild to moderate active Crohn's disease involving the ileum and/or the ascending colon. As an enema, Entocort is indicated for the induction and maintenance of clinical remission of distal ulcerative colitis in the rectum, sigmoid colon and descending colon. AstraZeneca has a partnership with Par Pharmaceutical for the commercialisation of Entocort in the US. About Tillotts Tillotts Pharma AG, part of the Zeria Group, is a fast-growing specialty pharma company with over 200 employees in Switzerland and abroad. Tillotts is dedicated to the development, in/out-licensing and commercialisation of innovative pharmaceutical products, medical devices and diagnostics, all in the field of gastroenterology. Tillotts successfully markets its own products Asacol® and Colpermin®, as well as VistaPrep® and in-licensed products, such as Simtomax®, in over 55 countries through its own affiliates within Europe and a carefully chosen network of gastroenterology-focused marketing partners throughout the world. For more information, please visit www.tillotts.com. About Zeria Zeria Pharmaceutical Co., Ltd., founded in 1955, based in Tokyo, Japan, focuses on R&D, manufacturing and sales of prescription drugs as well as OTC products. The company is listed on the First Section of Tokyo Stock Exchange (Stock code: 4559). Zeria holds a leading position within the gastroenterology field in Japan and operates internationally through a number of subsidiaries. For more information, please visit www.zeria.co.jp. About AstraZeneca AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection and neuroscience diseases. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information please visit: www.astrazeneca.com CONTACTS Media Enquiries Esra Erkal UK/Global +44 20 7604 8030 -Paler Vanessa UK/Global +44 20 7604 8037 Rhodes Ayesha UK/Global +44 20 7604 8034 Bharmal Jacob Lund Sweden +46 8 553 260   20 Michele US + 1 302 885 6351 Meixell Investor Enquiries UK Thomas +44 20 7604   8199   +44 7818   524185 Kudsk Larsen Eugenia Respiratory,   +44 20 7604   8233   +44 7884   735627 Litz Inflammation and Autoimmunity Nick Stone Cardiovascular and +44 17 6326 3994   +44 7717 618834 Metabolic   Disease Karl Hård Oncology +44 20 7604   8123 +44 7789   654364 Craig Infection,   +44 20 7604   8591   +44 7881   615764 Marks Neuroscience and Gastrointestinal   Disease Christer +44 20 7604 8126 +44 7827 836825 Gruvris US Dial / +1 301 398 3251 +1 866 381 7277 Toll-Free 17 July 2015 -ENDS-

Ads